Page 1 - reflections_newsletter

REFLECTIONS

Dyslipidaemia
Dyslipidaemia Global Newsletter #11 2026

TABLE OF CONTENTS Welcome back to the Reflections Dyslipidaemia Global Newsletter,
where an international Scientific Planning Committee (SPC)
KEY ARTICLES summarises and provides expert commentary on the latest clinical
and real-world evidence in the field of dyslipidaemia. These
Dyslipida
EPIDEMIOLOGY articles are chosen based on their significance to everyday clinical
practice. This newsletter highlights the near-universal presence
Prevalence, incidence, and definition of severe
hypertriglyceridemia: A comprehensive review and of non-optimal traditional risk factors preceding cardiovascular
weighted summary. Baass A, et al. J Clin Lipidol. 2025 Nov- events, explores the complex shift from focusing on high-
Dec;19(6):1550-1563. density lipoprotein cholesterol (HDL-C) quantity to evaluating
Very high prevalence of nonoptimally controlled its functionality, and delves into the varying epidemiological
traditional risk factors at the onset of cardiovascular definitions and global prevalence of severe hypertriglyceridaemia.
disease. Lee H, et al. J Am Coll Cardiol. 2025 Oct It also examines new evidence supporting stricter low-density
7;86(14):1017-1029. lipoprotein cholesterol (LDL-C) targets, translational advances in

TREATMENTS AND THERAPEUTICS lipid-lowering therapies (such as expanding proprotein convertase
Evolocumab in patients without a previous myocardial subtilisin/kexin type 9 [PCSK9] inhibition) and the promise of novel
infarction or stroke. Bohula EA, et al. N Engl J Med. 2026 oral agents, RNA interference, and gene editing technologies
Jan 8;394(2):117-127. to aggressively manage residual risk driven by targets like
lipoprotein(a). As with previous newsletters, we invite you to
The evolving therapeutic landscape of PCSK9 inhibition.
Mansfield BS, et al. Atherosclerosis. 2026 Feb 9;414 :120670. interact through links to short video commentaries from our SPC,
Lipoprotein(a)-lowering therapies: A promising future. links to videos or podcasts, along with hyperlinks to full articles for
Zhang J, et al. Eur Heart J. 2026 Feb 13:ehag092. Online in-depth study and reflection.
ahead of print. Prof. Farnier (Chair)
TARGETS AND BIOMARKERS SCIENTIFIC PLANNING COMMITTEE
Intensive LDL cholesterol targeting in atherosclerotic
cardiovascular disease. Lee YJ, et al. N Engl J Med. 2026 Prof. Michel Farnier Prof. Choong Hou Koh
Mar 28. Online ahead of print. (France) (Singapore)
HDL-C: Helpful, harmful, hopeful, or guilty by
association. McLean P, et al. J Clin Lipidol. 2025 Nov-
Dec;19(6):1564-1574. Prof. Augusto Lavalle Prof. Ahmed Shawky
Cobo (Egypt)
(Argentina)
ADDITIONAL ARTICLES OF INTEREST
Prof. Cristina Gavina Prof. Marcin Welnicki
(Portugal) (Poland)

EPIDEMIOLOGY

Prevalence, incidence, and definition of severe hypertriglyceridemia:
A comprehensive review and weighted summary.
Baass A, et al. J Clin Lipidol. 2025 Nov-Dec;19(6):1550-1563.

Triglycerides (TG) serve as the main reservoir of energy stored within the body; however, impairments in clearance or catabolism can lead
to elevated TG levels or pathological hypertriglyceridaemia (HTG). HTG can be classified as either primary, meaning it has a substantial
genetic component, or secondary, which results from external factors that increase susceptibility (obesity, uncontrolled diabetes, etc.).
Severe elevations in TG levels (known as severe hypertriglyceridaemia [sHTG]) pose significant clinical concerns due to the increased
risk of acute pancreatitis and cardiovascular (CV) complications, yet current clinical guidelines lack consistency in defining the condition.